Using artificial intelligence to diagnose a range of diseases, Sophia Genetics, a Switzerland-based start-up and genetics testing company, has become the world's largest network for molecular diagnostics. Mike Lynch, whose firm Invoke Capital has invested $18m, said that other companies “will struggle to catch up.” Using and analysing data from 100 hospitals, the company will diagnose over 80,000 patients in 2016. This data-rich ‘precision medicine,’ results in a faster and more accurate diagnosis, which in turn will lead to a specific, tailored treatment plan.
Using artificial intelligence to diagnose a range of diseases, Sophia Genetics, a Cambridge-based start-up and genetics testing company, has become the world's largest network for molecular diagnostics. Mike Lynch, whose firm Invoke Capital has invested $18m, said that other companies “will struggle to catch up.” Using and analysing data from 100 hospitals, the company will diagnose over 80,000 patients in 2016. This data-rich ‘precision medicine,’ results in a faster and more accurate diagnosis, which in turn will lead to a specific, tailored treatment plan.